| Title |
The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain
|
|---|---|
| Published in |
Clinical Rheumatology, February 2014
|
| DOI | 10.1007/s10067-014-2517-2 |
| Pubmed ID | |
| Authors |
Jarred Younger, Luke Parkitny, David McLain |
X Demographics
The data shown below were collected from the profiles of 252 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 79 | 31% |
| United Kingdom | 13 | 5% |
| Canada | 9 | 4% |
| Australia | 5 | 2% |
| Germany | 2 | <1% |
| Japan | 2 | <1% |
| Spain | 2 | <1% |
| Ireland | 2 | <1% |
| Venezuela, Bolivarian Republic of | 2 | <1% |
| Other | 15 | 6% |
| Unknown | 121 | 48% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 202 | 80% |
| Practitioners (doctors, other healthcare professionals) | 24 | 10% |
| Scientists | 21 | 8% |
| Science communicators (journalists, bloggers, editors) | 5 | 2% |
Mendeley readers
The data shown below were compiled from readership statistics for 455 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 1% |
| United Kingdom | 2 | <1% |
| Turkey | 1 | <1% |
| Canada | 1 | <1% |
| Brazil | 1 | <1% |
| Spain | 1 | <1% |
| Belgium | 1 | <1% |
| Unknown | 443 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 69 | 15% |
| Other | 63 | 14% |
| Student > Doctoral Student | 51 | 11% |
| Student > Master | 45 | 10% |
| Student > Bachelor | 39 | 9% |
| Other | 103 | 23% |
| Unknown | 85 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 193 | 42% |
| Pharmacology, Toxicology and Pharmaceutical Science | 26 | 6% |
| Agricultural and Biological Sciences | 22 | 5% |
| Nursing and Health Professions | 21 | 5% |
| Biochemistry, Genetics and Molecular Biology | 20 | 4% |
| Other | 77 | 17% |
| Unknown | 96 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 525. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 May 2024.
All research outputs
#49,307
of 25,978,998 outputs
Outputs from Clinical Rheumatology
#4
of 3,332 outputs
Outputs of similar age
#361
of 347,327 outputs
Outputs of similar age from Clinical Rheumatology
#1
of 88 outputs
Altmetric has tracked 25,978,998 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,332 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.4. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 347,327 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 88 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.